Although collectively the research literature supports a role for BARD1 variants in the etiology of cancer, there is insufficient evidence to translate findings to clinical settings for the purposes of providing cancer risk in variant carriers or managing cancer care as is currently available for carriers of variants in known high risk genes, such as BRCA1 and BRCA2 [144]. This evidence concerns the gene BRCA2 and cancer.